 "Lupin Pharma")
Lupin Ltd, India's third-largest drugmaker by sales, reported a 21% jump in its quarterly profit, beating analysts' estimates, helped by higher sales of its diabetes products in the United States.
Net profit for the third quarter rose to Rs 6.33 billion ($94.44 million) from Rs 5.25 billion a year ago. Analysts on average expected a profit of Rs 6.29 billion, according to Thomson Reuters.
($1 = Rs 67.0250)
